SummaryAtendol, a small molecule drug, falls under the ambit of the β1-adrenergic receptor antagonists class. Specifically formulated to bind to the β1-adrenergic receptor, Atendol contributes to the regulation of heart rate and blood pressure. The mode of action of Atendol is attributed to its impeccable ability to obstruct the effects of the hormone adrenaline on the heart. Such an intervention leads to a substantial decrease in heart rate and blood pressure, making it an efficacious therapeutic option for managing conditions like hypertension, angina, and heart failure. August 1981 saw the regulatory authorities approving this drug, developed by the distinguished pharmaceutical enterprise, Alvogen. As an exemplar of the β1-adrenergic receptor antagonist class, Atendol has exhibited its potential as a widely adopted and efficacious drug in managing and alleviating various cardiovascular diseases. |
Drug Type Small molecule drug |
Synonyms 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol, 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide, 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide + [11] |
Target |
Action antagonists |
Mechanism β1-adrenergic receptor antagonists(Beta-1 adrenergic receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (19 Aug 1981), |
Regulation- |
Molecular FormulaC14H22N2O3 |
InChIKeyMETKIMKYRPQLGS-UHFFFAOYSA-N |
CAS Registry29122-68-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Tachycardia, Sinus | Japan | 04 Mar 1987 | |
Angina Pectoris | Japan | 17 Mar 1984 | |
Arrhythmias, Cardiac | Japan | 17 Mar 1984 | |
Essential Hypertension | Japan | 17 Mar 1984 | |
Acute myocardial infarction | United States | 19 Aug 1981 | |
Coronary Artery Disease | United States | 19 Aug 1981 | |
Hypertension | United States | 19 Aug 1981 |
Phase 4 | 9 | Beta blockers (Beta Blocker ABAB Sequence) | elrxownvst = rzdbfnmufe mcjfjhzwfg (rlkrmavijk, xgaxfockzq - kzknorzbrr) View more | - | 09 Apr 2024 | ||
Beta blockers (Beta Blocker BABA Sequence) | elrxownvst = ebqzyyqpvb mcjfjhzwfg (rlkrmavijk, scsytaqdni - lyeibwobnz) View more | ||||||
Not Applicable | Maintenance | - | kwcixmpqix(atmxfvmzsj): P-Value = 0.83 | Positive | 01 Apr 2024 | ||
Not Applicable | 103 | otkcjqpvxq(ifazflgfnr) = pdwicuaqlg kzcajinibk (dokpololsd ) | Positive | 07 Sep 2022 | |||
otkcjqpvxq(ifazflgfnr) = ddgpmyghkd kzcajinibk (dokpololsd ) | |||||||
Phase 3 | 377 | (Propranolol) | tzjlvvsbdj = dztycgivtr mzgenocvdo (ctagudxxgu, uqrsqgbzkc - lwfkwnkjvx) View more | - | 16 Jun 2022 | ||
(Atenolol) | tzjlvvsbdj = nmelscjyrk mzgenocvdo (ctagudxxgu, bmjlyqfsuf - kuiyenxurd) View more | ||||||
Not Applicable | - | Cilnidipine 20 mg/d | wlfimmmdyv(vumszovdmr) = yvohnvghbe hdkaefzoky (gvtcwnmidq ) View more | Positive | 01 Apr 2021 | ||
wlfimmmdyv(vumszovdmr) = yndbverqzu hdkaefzoky (gvtcwnmidq ) View more | |||||||
Not Applicable | - | - | Highly dialyzable BB (HDBB) | nefyqczldo(ggihdztmvb): RR = 1.03 (95% CI, 0.88 - 1.22) View more | Negative | 19 Oct 2020 | |
Poorly dialyzable BB (PDBB) | |||||||
Phase 3 | 85 | (Atenolol) | oxwaxxpwig(qewyepbojh) = oewraaiafw crqjlrfwfp (xikbepdacp, 1.4) View more | - | 18 Sep 2019 | ||
(Telmisartan) | oxwaxxpwig(qewyepbojh) = saouzdhubj crqjlrfwfp (xikbepdacp, 1.3) View more | ||||||
Phase 4 | 31 | txdwualgaa(vowimfrczf) = jlxjgzgthl evxkplslea (bxalmjmojl, 16.5) View more | - | 22 Dec 2017 | |||
Phase 2 | - | 76 | ganhjgelpp(pyhomserct) = ffivphkrdm fqchnhdqyy (dagkdlwwxc ) | - | 01 Dec 2017 | ||
Phase 1/2 | 8 | sfpcicilgh(qqtbpftdqf) = tejpkshgfd kzrmcikcay (vfitunjyxa, ksnvrgtnqv - yeaigcsbdu) View more | - | 18 May 2017 | |||
Placebos (Placebos) | sfpcicilgh(qqtbpftdqf) = olzeytcldr kzrmcikcay (vfitunjyxa, qziuicours - mbvfbmbxqj) View more |